{"id":"W7116985745","doi":"10.1136/bmjno-2025-001313","title":"Study protocol for a multicentre, randomised, double-blinded, placebo-controlled, multi-arm, multi-stage, trial of SpironolacTone and famciclOovir in the treatment of Progressive Multiple Sclerosis to prevent disability progression: the STOP-MS trial","year":2025,"lang":"en","type":"article","venue":"BMJ Neurology Open","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Infection and Immunity","funders":"National Health and Medical Research Council; Teva Pharmaceutical Industries; Mitsubishi Tanabe Pharma Corporation; GlaxoSmithKline; Biogen; Sanofi","keywords":"Clinical trial; Multiple sclerosis; Spironolactone; Protocol (science); Administration (probate law)","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02159991,0.006532639,0.01058662,0.001925638,0.004273578,0.004359413,0.004392464,0.009049289,0.2663418],"category_scores_gemma":[0.0296682,0.003516518,0.004118707,0.003151739,0.00338021,0.004656712,0.002149762,0.01040597,0.05855913],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004436519,"about_ca_system_score_gemma":0.01884135,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001841506,"about_ca_topic_score_gemma":0.004798691,"domain_scores_codex":[0.9855466,0.007754648,0.001767918,0.002244313,0.001358447,0.001328008],"domain_scores_gemma":[0.9871488,0.002688601,0.002309906,0.002199125,0.002787693,0.002865925],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7164903,0.009707081,0.001106558,0.04296441,0.001550888,0.0005516181,0.0006684517,0.001336595,0.002765228,0.01493082,0.1382889,0.06963919],"study_design_scores_gemma":[0.7757774,0.01657609,0.002034327,0.008023214,0.0006945986,0.0001986761,0.0001559565,0.001852063,0.0007397162,0.005948142,0.1878341,0.0001656768],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"protocol","genre_gemma":"protocol","genre_scores_codex":[0.0009253312,0.0005784614,0.002028583,0.0004174149,0.0009544636,0.9861855,0.005949861,0.0001721589,0.002788334],"genre_scores_gemma":[0.001724358,0.0002859305,0.002574412,0.0005098419,0.0001915928,0.9918289,0.001006179,0.00002316102,0.001855703],"genre_candidate":"protocol","genre_consensus":"protocol","teacher_disagreement_score":0.2663418,"threshold_uncertainty_score":0.8910021,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2817327530458859,"score_gpt":0.5059866021101453,"score_spread":0.2242538490642594,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}